Nimbus Therapeutics CEO Jeb Keiper at #JPM24 (Brian Benton Photography)
May 23, 2024 05:00 PM EDT
R&D

Af­ter $4B Take­da deal, Nim­bus lays out ‘grand’ hopes for its next-gen im­munother­a­py drug

Andrew Dunn

Senior Biopharma Correspondent

Just over a year ago, Nim­bus Ther­a­peu­tics closed one of the biggest sin­gle-drug deals in biotech, sell­ing its TYK2 in­hibitor to Take­da …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times